Literature DB >> 1869557

Heparin strongly decreases the rate of inhibition of neutrophil elastase by alpha 1-proteinase inhibitor.

K J Frommherz1, B Faller, J G Bieth.   

Abstract

Heparin depresses the second-order rate constant ka for the inhibition of neutrophil elastase by alpha 1-proteinase inhibitor. High molecular mass heparin decreases ka from 1.3 x 10(7) M-1 s-1 to a limit of 4.6 x 10(4) M-1 s-1. Low molecular mass heparin is about 7-fold less effective. Dermatan sulfate and chondroitin sulfate are less efficient. Heparin preparations used in clinical care also strongly depress ka when tested at concentrations corresponding to their clinical efficacy. Heparin also decreases the ka for the elastase/eglin c and the cathepsin G/alpha 1-proteinase inhibitor systems but not that for the alpha 1-proteinase inhibitor/pancreatic elastase or trypsin pairs. These results, together with Sepharose-heparin binding studies, indicate that the ka-depressing effect of the polymer is related to its ability to form a tight complex with elastase but not with alpha 1-proteinase inhibitor. One mol of high molecular mass heparin binds 3 mol of neutrophil elastase with a Kd of 3.3 nM. Low molecular mass heparin binds elastase with a 1:1 stoichiometry and a Kd of 89 nM. For both heparins ka is lowest when elastase is fully saturated with heparin. From this we conclude that heparin decreases ka, because the heparin-elastase complex is able to slowly react with alpha 1-proteinase inhibitor and not because the inhibitor slowly dissociates the heparin-elastase complex. These findings may have important pathophysiological bearing.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1869557

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  18 in total

Review 1.  Intracellular proteoglycans.

Authors:  Svein Olav Kolset; Kristian Prydz; Gunnar Pejler
Journal:  Biochem J       Date:  2004-04-15       Impact factor: 3.857

Review 2.  Neutrophil elastase, proteinase 3, and cathepsin G as therapeutic targets in human diseases.

Authors:  Brice Korkmaz; Marshall S Horwitz; Dieter E Jenne; Francis Gauthier
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

3.  Neonatal Bone Marrow Transplantation in MPS IIIA Mice.

Authors:  Adeline A Lau; N Jannah Shamsani; Leanne K Winner; Sofia Hassiotis; Barbara M King; John J Hopwood; Kim M Hemsley
Journal:  JIMD Rep       Date:  2012-08-10

4.  A novel locust (Schistocerca gregaria) serine protease inhibitor with a high affinity for neutrophil elastase.

Authors:  Michèle Brillard-Bourdet; Ahmed Hamdaoui; Eric Hajjar; Christian Boudier; Nathalie Reuter; Laurence Ehret-Sabatier; Joseph G Bieth; Francis Gauthier
Journal:  Biochem J       Date:  2006-12-15       Impact factor: 3.857

Review 5.  Considerations for Soluble Protein Biomarker Blood Sample Matrix Selection.

Authors:  Joel A Mathews; Yan G Ni; Connie Wang; Jon E Peterson; Chad Ray; Xuemei Zhao; Daoyu Duan; Sara Hamon; John Allinson; Martha Hokom; Greta Wegner
Journal:  AAPS J       Date:  2020-01-29       Impact factor: 4.009

6.  The 1.8 A crystal structure of human cathepsin G in complex with Suc-Val-Pro-PheP-(OPh)2: a Janus-faced proteinase with two opposite specificities.

Authors:  P Hof; I Mayr; R Huber; E Korzus; J Potempa; J Travis; J C Powers; W Bode
Journal:  EMBO J       Date:  1996-10-15       Impact factor: 11.598

7.  On the Process of Discovering Leads That Target the Heparin-Binding Site of Neutrophil Elastase in the Sputum of Cystic Fibrosis Patients.

Authors:  Shravan Morla; Nehru Viji Sankaranarayanan; Daniel K Afosah; Megh Kumar; Apparao B Kummarapurugu; Judith A Voynow; Umesh R Desai
Journal:  J Med Chem       Date:  2019-05-28       Impact factor: 7.446

8.  N-Arylacyl O-sulfonated aminoglycosides as novel inhibitors of human neutrophil elastase, cathepsin G and proteinase 3.

Authors:  Ioana Craciun; Amanda M Fenner; Robert J Kerns
Journal:  Glycobiology       Date:  2016-02-05       Impact factor: 4.313

9.  Cellular localization and regional distribution of an angiotensin II-forming chymase in the heart.

Authors:  H Urata; K D Boehm; A Philip; A Kinoshita; J Gabrovsek; F M Bumpus; A Husain
Journal:  J Clin Invest       Date:  1993-04       Impact factor: 14.808

Review 10.  Sulfated Non-Saccharide Glycosaminoglycan Mimetics as Novel Drug Discovery Platform for Various Pathologies.

Authors:  Daniel K Afosah; Rami A Al-Horani
Journal:  Curr Med Chem       Date:  2020       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.